XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet
Consolidated Statements of Income
(loss)
  
Year ended December 31, 2022
 
 
Consolidated Balance Sheets
  
December 31, 2022
 
 
  
As
previously
reported
 
 
Adjustment
 
 
As
revised
 
 
 
  
As
previously
reported
 
 
Adjustment
 
 
As
revised
 
 
  
U.S $ in millions (except per share
amounts)
 
 
 
  
U.S $ in millions (except per share
amounts)
 
Other asset impairments, restructuring and other items
  
$
414
 
 
 
98
 
 
 
512
 
 
Deferred income taxes
  
$
1,453
 
 
 
5
 
 
 
1,458
 
Operating income (loss)
  
 
(2,099
) 
 
 
(98
) 
 
 
(2,197
) 
 
Total assets
  
 
44,006
 
 
 
5
 
 
 
44,011
 
Income (loss) before income taxes
  
 
(3,065
) 
 
 
(98
) 
 
 
(3,163
) 
 
Other taxes and long-term liabilities
  
 
3,847
 
 
 
98
 
 
 
3,945
 
Income taxes (benefit)
  
 
(638
) 
 
 
(5
) 
 
 
(643
) 
 
Total long-term liabilities
  
 
23,846
 
 
 
98
 
 
 
23,944
 
Net income (loss)
  
 
(2,406
) 
 
 
(93
) 
 
 
(2,499
) 
 
Total liabilities
  
 
35,315
 
 
 
98
 
 
 
35,413
 
Net income (loss) attributable to Teva
  
 
(2,353
) 
 
 
(93
) 
 
 
(2,446
) 
 
Teva shareholders’ equity:
  
 
 
Earnings (loss) per share attributable to ordinary shareholders:
  
 
 
 
Accumulated deficit
  
 
(12,882
) 
 
 
(93
) 
 
 
(12,975
) 
Basic
  
$
(2.12
) 
 
 
(0.08
) 
 
 
(2.20
) 
 
Total equity
  
 
8,691
 
 
 
(93
) 
 
 
8,598
 
Diluted
  
$
(2.12
) 
 
 
(0.08
) 
 
 
(2.20
) 
 
Total liabilities and equity
  
$
44,006
 
 
 
5
 
 
 
44,011